Skip to main content
Clinical Trials/NL-OMON20824
NL-OMON20824
Recruiting
Not Applicable

Clinical Validation of a Point of Care (POC) Test for the Measurement of Infliximab (IFX) or Adalimumab (ADL) Levels in the Serum of Inflammatory Bowel Disease (IBD) Patients

ProciseDx0 sites320 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
ProciseDx
Enrollment
320
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
ProciseDx

Eligibility Criteria

Inclusion Criteria

  • 1\.Adult (\=16 years old) Males and females with either CD or UC.
  • 2\.Patients must have a confirmed diagnosis of CD or UC based on results of a complete medical evaluation and assessment by a physician specialized in inflammatory bowel disease.
  • 3\.Patients must be undergoing maintenance phase IFX or ADL therapy at the time of the first blood collection used for the current study
  • 4\.Patients must have at least 24 months of follow up after the baseline sample.
  • 5\.Written informed consent must be provided.

Exclusion Criteria

  • 1\.Patients not undergoing maintenance phase IFX, ADL or biosimilar therapy at time of baseline sample collection.
  • 2\.Patients not diagnosed with either CD or UC.
  • 3\.Receipt of any blood products within 3 months prior to the baseline sample collection
  • 4\.Participation in a clinical trial at the baseline sample collection or within the 8 weeks prior to the baseline sample collection.

Outcomes

Primary Outcomes

Not specified

Similar Trials